Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by BB Biotech
PSD Bank Rhein-Ruhr eG
Lonza Nominates Pearl Huang as Independent Board Member Lonza Group AG / Key word(s): Personnel Lonza Nominates Pearl Huang as Independent Board Member 30.09.2026 / 07:00 CET/CEST _____________________________________________________________ * Pearl Huang brings extensive leadership experience in the global pharmaceutical and biotechnology industries and deep scientific expertise.
ROSEN, A TOP RANKED LAW FIRM, Encourages WM Technology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MAPS - 24.10.24 - News - ARIVA.DE
New York, New York--(Newsfile Corp. - October 24, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of WM Technology, Inc. (NASDAQ: MAPS) between May 25, 2021, and September 24, 2024, both dates inclusive (the "Class Period"), of the important December 16, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.
Summit Materials Discloses Receipt of a Non-Binding Acquisition Proposal
PR Newswire DENVER, Oct. 24, 2024 /PRNewswire/ -- Summit Materials, Inc. (NYSE: SUM) ("Summit," "Summit Materials," "Summit Inc." or the "Company") today disclosed that it has received a non-binding acquisition proposal. The Company has held initial discussions with the interested party, and, in consultation with its advisors, Summit's Board of Directors will carefully evaluate the proposal to determine the course of action it believes is in the best interests of the Company and its shareholders.
SIKA SETS NEW RECORDS IN SALES AND PROFIT - ORGANIC GROWTH ACCELERATES FURTHER
Freitag, 25.10.2024 05:00 von GlobeNewswire | Aufrufe: 14 Chemikalien und ein Reagenzglas (Symbolbild).
Kuaishou Launches Full Beta Testing for 'Kling AI' to Global Users, Elevates Model Capabilities
Along with the upgrade, Kling AI has also officially launched an all-new subscription program for users in mainland China. Users can choose from three subscription tiers on Kling AI's official website: Gold, Platinum and Diamond, with monthly prices of RMB66, RMB266 and RMB666, respectively. The pricing for each tier is equivalent to 660, 3,000 and 8,000 Inspiration Credits, which can generate approximately 66, 300, or 800 standard videos.
PEOPLES FINANCIAL SERVICES CORP. Reports Unaudited Second Quarter and Year to Date 2024 Earnings
Top-News Donnerstag, 25.07.2024 20:33 von PR Newswire Ein Mann liest Wirtschaftsnachrichten (Symbolbild). pixabay.com PR Newswire SCRANTON, Pa., July 25, 2024 /PRNewswire/ -- Peoples Financial Services Corp. ("Peoples" or the "Company") (NASDAQ: PFIS), the bank holding company for Peoples Security Bank and Trust Company, today reported unaudited financial results at and for the three and six months ended June 30, 2024.
[Sponsored] Mit Algorithmen zu Blockbustern
Künstliche Intelligenz und maschinelles Lernen mithilfe von Algorithmen sind in der Medikamentenentwicklung in zweierlei Hinsicht eine disruptive Technologie. Zum einen sind sie ein Vehikel, um Moleküle für die klinische Entwicklung zeit- und kostensparender zu identifizieren. Zum anderen lassen sich klinische Studien dank der Vielzahl der zur Verfügung stehenden Daten so aufsetzen und Patienten so auswählen, dass sich Kosten, Zeitraum und vor allem das Risiko von Fehlschlägen deutlich reduzieren.
EQS-News: BB BIOTECH AG: Mit Algorithmen zu Blockbustern (deutsch)
BB BIOTECH AG: Mit Algorithmen zu Blockbustern ^ EQS-News: BB BIOTECH AG / Schlagwort(e): Marktbericht BB BIOTECH AG: Mit Algorithmen zu Blockbustern 03.05.2023 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
BB Biotech's Dallas Webb on investing in biotech stocks for the future
This week on The Armchair Trader podcast we talk to BB Biotech (SWX:BION), the $4.5bn Swiss-listed investment fund, about prospects for the biotech sector in 2022. Dallas Webb, portfolio manager for fund, joined us to discuss, among other things, their giant trade on Moderna which went amazingly well for the fund in 2020. BB Biotech is one of the largest investors in the world in fast-growing biotech stocks.
Swiss-listed BB Biotech looks set for dividend hike after tough year
21st January 2022 Stuart Fieldhouse Equities Investment Trusts, The Biotech Sector, Members Only, BB Biotech Swiss-listed investment company BB Biotech (SWX:BION) says it is looking back on a tough year for the biotechnology sector even as it reported a total share return of 8.3% in Swiss francs (13.3% in Euro). Some of this was attributed to the performance of the USD, but the biotech fund saw its net asset value off by over 14% for the year.
Moderna mit ihrem COVID-19-Impfstoff steht stellvertretend für die Innovationskraft der gesamten Biotechindustrie
Weniger als elf Monate dauerte es von der Entschlüsselung des genetischen Codes des SARS-CoV-2-Virus bis zum Zulassungsantrag für die ersten zwei Impfstoffe, die eine globale Eindämmung der Coronapandemie bewirken sollen. «Die von Moderna verwendete mRNA-Technologie ist ein gutes Beispiel dafür, wie innovative Technologien aus den Labors von Biotechfirmen den medizinischen Fortschritt vorantreiben», erklärt Dr. Daniel Koller, Leiter Investment Team.
BB Biotech holds steady in the second quarter
Major headwinds caused by various factors such as the talk of the US federal government imposing drug price controls and the general impression that the bull market is on its last leg weighed on investor sentiment in the healthcare sector during the second quarter. BB Biotech shares were not completely immune to these developments and delivered a return of 1.2% in EUR for the second quarter and 8.2% for the first half of 2018.
Biotech in the fight against cancer
Big players in the healthcare sector are desperate to differentiate their approved ‘checkpoint inhibitors’ (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new drugs. Biotechnology firms are developing many of these next-generation combination agents as well as continuing to strengthen their positions in treatments for more niche medical problems. This makes for an interesting area for investors.
Biotech outlook: Increasing strength of innovation in 2018
This in turn will enable continued investment in their research pipelines and catapult them to the next level of success, secured by increasingly diverse sources of growth. Acquisitions and alliances will remain an additional source of diversification and subsequent growth.
BB Biotech - double digit return and record dividend
With a total return for BB Biotech’s shareholders of 23.1% in CHF and 13.1% in EUR buoyed by the euro’s substantial appreciation against the dollar, BB Biotech delivered a strong performance in 2017. The underlying portfolio performed well, ending the year up 23.4% in CHF, 12.5% in EUR and 29.2% in USD – which is 7.5% ahead of the Nasdaq Biotech Index .Consolidated, but not yet audited, full year 2017 data showed a net gain of CHF 688 mn..
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with BB
Contact BB, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack